Document Detail

Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
MedLine Citation:
PMID:  20722702     Owner:  NLM     Status:  MEDLINE    
Achievement of complete response (CR) is a new goal of therapy for multiple myeloma (MM). By sensitive methods, the depth of response can be measured even among the patients in CR. We used a sensitive real-time quantitative polymerase chain reaction by allele-specific primers (qASO-PCR) to assess the level of minimal residual disease (MRD) in bone marrow of 37 patients with myeloma who had achieved CR/near-to-CR after autologous or allogeneic stem cell transplantation (SCT). Allele-specific primers could be successfully designed for 86% of patients. Three to six months after autotransplantation, the PCR target was not detectable in 53% of patients (16/30 patients), and the respective figure after allotransplantation was 71% (5/7 patients); the median sensitivity of PCR assay was <0.002%. The proportion of patients without detectable PCR target was 22% of all autotransplanted patients. A threshold level of 0.01% in the qASO-PCR assay 3-6 months after SCT was found to be a useful cut-off limit to divide the patients into two prognostic groups: MRD low/negative vs. MRD high. Low/negative MRD after SCT was a significant predictive factor for the prolongation of progression free (70 vs. 19 months; P = 0.003) and suggestively also for overall survival. We conclude that not only CR but also its depth is important for the long-term outcome in MM.
Mervi Putkonen; Veli Kairisto; Vesa Juvonen; Tarja-Terttu Pelliniemi; Auvo Rauhala; Maija Itälä-Remes; Kari Remes
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of haematology     Volume:  85     ISSN:  1600-0609     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-22     Completed Date:  2010-12-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  416-23     Citation Subset:  IM    
Copyright Information:
© 2010 John Wiley & Sons A/S.
Department of Medicine, Turku University Central Hospital, Vaasa, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow / pathology
DNA Primers
Disease-Free Survival
Hematopoietic Stem Cell Transplantation / methods*
Middle Aged
Multiple Myeloma / diagnosis*,  mortality,  therapy*
Neoplasm, Residual / diagnosis*
Polymerase Chain Reaction / methods*,  standards
Predictive Value of Tests*
Remission Induction / methods
Sensitivity and Specificity
Survival Rate
Treatment Outcome
Reg. No./Substance:
0/DNA Primers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Longer survival associated with HLA-A*03, B*14 among 212 hemochromatosis probands with HFE C282Y hom...
Next Document:  The incidence of traumatic brain injury in an adult population - how to classify mild cases?